gastric cancer
Showing NaN - NaN of 88
Gastric Cancer Trial in Shanghai (NK510, Tislelizumab,atezolizumab or Trastuzumab)
Enrolling by invitation
- Gastric Cancer
- NK510
- Tislelizumab,atezolizumab or Trastuzumab
-
Shanghai, ChinaShanghai Tenth People's Hospital
Oct 22, 2023
Gastric Cancer, HER2-low-expressing Gastric Cancer Trial in Shanghai (Disitamab Vedotin, Toripalimab)
Recruiting
- Gastric Cancer
- HER2-low-expressing Gastric Cancer
- Disitamab Vedotin
- Toripalimab
-
Shanghai, ChinaShanghai East Hospital
Oct 9, 2023
Gastric Cancer Trial in Shanghai (sintilimab+metronomic PLOF)
Recruiting
- Gastric Cancer
- sintilimab+metronomic PLOF
-
Shanghai, ChinaHuashan Hospital, Fudan University
Sep 22, 2023
Gastric Cancer Response to Neoadjuvant Chemotherapy
Not yet recruiting
- Gastric Cancer
- +2 more
- Neoadjuvant Chemotherapy
-
Beijing, China
- +21 more
Sep 6, 2023
Gastric Cancer, Chemo Effect, Immune Checkpoint Inhibitor Trial in Shanghai (Sintilimab, paclitaxel-albumin, oxaliplatin, 5-FU)
Recruiting
- Gastric Cancer
- +2 more
- Sintilimab, paclitaxel-albumin, oxaliplatin, 5-FU
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center
Aug 1, 2023
Gastric Cancer Trial in Shanghai (Serplulimab, Trastuzuma, Chemotherapy)
Recruiting
- Gastric Cancer
- Serplulimab
- +2 more
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center
Jul 27, 2023
Gastric Cancer Trial in China (Experimental dose: modified XELOX + sintilimab, Standard dose: standard XELOX + sintilimab)
Recruiting
- Gastric Cancer
- Experimental dose: modified XELOX + sintilimab
- Standard dose: standard XELOX + sintilimab
-
Guangzhou, Guangdong, China
- +9 more
Jun 23, 2023
Sarcoma, Carcinoma, Breast Cancer Trial in Shanghai (Recombinant oncolytic herpes simplex virus type 1 (R130))
Recruiting
- Sarcoma
- +8 more
- Recombinant oncolytic herpes simplex virus type 1 (R130)
-
Shanghai, Jiangsu, ChinaXuzhou Second People's Hospital
May 8, 2023
Gastric Cancer Trial in Shanghai (68Ga-FAPI-04 PET/CT and 18F-FDG PET/CT)
Recruiting
- Gastric Cancer
- 68Ga-FAPI-04 PET/CT and 18F-FDG PET/CT
-
Shanghai, Shanghai, ChinaShanghai Ruijin Hospital
Dec 2, 2022
Gastric Cancer, Small-cell Lung Cancer Trial in China, Korea, Republic of, Taiwan (EP0057, Olaparib tablets)
Not yet recruiting
- Gastric Cancer
- Small-cell Lung Cancer
- EP0057
- Olaparib tablets
-
Shanghai, Changning District, 交通大学 邮政编码, China
- +20 more
Nov 1, 2022
Hypoxia, Gastric Cancer, Sedation Complication Trial in Shanghai, Jiaxing, Nanchang (Remimazolam tosylate, Propofol)
Recruiting
- Hypoxia
- +3 more
- Remimazolam tosylate
- Propofol
-
Shanghai, Shanghai, China, China
- +4 more
Oct 7, 2022
Gastric Cancer Trial in Shanghai (laparoscopy-assisted distal gastrectomy Group, Totally laparoscopic distal gastrectomy)
Recruiting
- Gastric Cancer
- laparoscopy-assisted distal gastrectomy Group
- Totally laparoscopic distal gastrectomy
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center
Sep 12, 2022
Gastric Cancer Trial in Shanghai (Total Gastrectomy)
Recruiting
- Gastric Cancer
- Total Gastrectomy
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center
Sep 8, 2022
Hypoxia, Gastric Cancer, Gastric Polyp Trial in Zhengzhou, Shanghai, Kunming (nasal mask oxygen kit, regular nasal cannula)
Recruiting
- Hypoxia
- +5 more
- nasal mask oxygen kit
- regular nasal cannula
-
Zhengzhou, Henan, China
- +2 more
Sep 6, 2022
Gastric Cancer, Gastroesophageal Junction Cancer, HER2-positive Gastric Cancer Trial in Worldwide (margetuximab, Retifanlimab,
Active, not recruiting
- Gastric Cancer
- +2 more
- margetuximab
- +4 more
-
Scottsdale, Arizona
- +72 more
Aug 24, 2022
Gastric Cancer, Gastroesophageal Junction Cancer Trial in China (Pembrolizumab, Placebo, Cisplatin)
Recruiting
- Gastric Cancer
- Gastroesophageal Junction Cancer
- Pembrolizumab
- +7 more
-
Beijing, Beijing, China
- +12 more
Aug 17, 2022
Gastric Cancer Trial in Shanghai (camrelizumab+chemo, Chemotherapy)
Recruiting
- Gastric Cancer
-
Shanghai, Shanghai, ChinaRuijin Hospital
Aug 9, 2022
Gastric Cancer Trial in China, Korea, Republic of, United States (IDX-1197+XELOX, IDX-1197+Irinotecan)
Recruiting
- Gastric Cancer
-
Los Angeles, California
- +11 more
Aug 7, 2022